FDA Moves to Bar Semaglutide, Tirzepatide and Liraglutide From the 503B Bulks List

A May 2026 Proposal Would Cut Off the Bulk-Compounded Supply Chain Many Telehealth and Medical Spa Billing Models Depend On

Rcmaxis Billing & Policy Update  ·  Posted November 2, 2026  ·  Source: FDA Federal Register Notice 2026-08552, published May 1, 2026

What's Changing and When

On May 1, 2026, FDA published a Federal Register notice (Docket FDA-2018-N-3240, document 2026-08552) proposing to exclude three drugs, semaglutide, tirzepatide and liraglutide, from the 503B bulk drug substances list entirely. A 503B outsourcing facility compounds in bulk under federal rules and can ship product without a patient-specific prescription already in hand, which is the pathway that let telehealth platforms and medical spas scale compounded GLP-1 programs quickly during the 2022 to 2024 shortage years. If this proposal is finalized, that pathway closes for these three drugs specifically, regardless of how a given practice bills or markets the resulting product.

FDA's reasoning is narrow and specific, and it rejects the arguments that have kept this supply chain running. For semaglutide, the agency found nominators didn't identify patients for whom the FDA-approved strengths, routes or formulations were actually unsuitable, and didn't justify alternative forms like buccal, sublingual or oral capsule versions. For tirzepatide, FDA noted that concerns about injection discomfort or general patient preference don't establish medical unsuitability, the actual legal bar. For liraglutide, the proposed strength already matched the approved product, with no patient-specific unsuitability identified at all. Across all three, FDA was explicit that shortages, backorders, cost and convenience don't meet the "clinical need" standard the law requires.

Why This Matters for Billing, Not Just Supply

A practice that bills insurance, Medicare or even cash-pay patients for a compounded GLP-1 sourced through 503B bulk compounding is building a billing and documentation workflow on top of a supply chain FDA has already signaled it intends to close. If the proposal is finalized while your practice still has active patients on a 503B-sourced product, you'll need an alternative supply plan, likely patient-specific 503A compounding or transitioning patients to the FDA-approved branded product, with no guaranteed transition window once the rule takes effect.

This also reframes the billing-compliance conversation around these drugs. A practice currently justifying its compounded GLP-1 program on shortage or cost grounds is relying on exactly the reasoning FDA has already rejected in this proposal. That's worth revisiting now, while there's still time to build a documentation record based on genuine, patient-specific medical necessity rather than the supply and cost arguments this proposal directly addresses and dismisses.

What to Do Now

Identify every patient currently on a compounded semaglutide, tirzepatide or liraglutide product sourced through 503B bulk compounding, and confirm with your compounding pharmacy whether they're 503A or 503B. For any 503B-sourced patient, start the conversation now about a transition plan to either patient-specific 503A compounding or the FDA-approved branded product, rather than waiting for a final rule announcement to force the timeline.

Our compounded GLP-1 billing compliance guide covers the broader False Claims Act and documentation exposure this supply-chain shift sits inside, and our GLP-1 and obesity medicine billing guide covers how to bill the FDA-approved branded products correctly once a transition happens.